260 related articles for article (PubMed ID: 16552574)
1. Radiation recall phenomenon secondary to capecitabine: possible role of thymidine phosphorylase.
Saif MW; Black G; Johnson M; Russo S; Diasio R
Cancer Chemother Pharmacol; 2006 Dec; 58(6):771-5. PubMed ID: 16552574
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase.
Saif MW; Black G; Roy S; Bell D; Russo S; Eloubeidi MA; Steg A; Johnson MR; Zelterman D; Diasio RB
Cancer J; 2007; 13(4):247-56. PubMed ID: 17762760
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome.
Saif MW; Eloubeidi MA; Russo S; Steg A; Thornton J; Fiveash J; Carpenter M; Blanquicett C; Diasio RB; Johnson MR
J Clin Oncol; 2005 Dec; 23(34):8679-87. PubMed ID: 16314628
[TBL] [Abstract][Full Text] [Related]
4. Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase/dihydropyrimidine dehydrogenase ratio and its correlation with survival.
Saif MW; Hashmi S; Bell D; Diasio RB
Expert Opin Drug Saf; 2009 Sep; 8(5):507-14. PubMed ID: 19663627
[TBL] [Abstract][Full Text] [Related]
5. Radiation recall gastritis secondary to erlotinib in a patient with pancreatic cancer.
Graziani C; Hegde S; Saif MW
Anticancer Res; 2014 Dec; 34(12):7339-43. PubMed ID: 25503169
[TBL] [Abstract][Full Text] [Related]
6. Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer.
Boskos CS; Liacos C; Korkolis D; Aygerinos K; Lamproglou I; Terpos E; Stoupa E; Baltatzis G; Beroukas K; Papasavvas P; Dimopoulos MA; Bamias A
J Surg Oncol; 2010 Oct; 102(5):408-12. PubMed ID: 19877119
[TBL] [Abstract][Full Text] [Related]
7. Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects.
Blanquicett C; Saif MW; Buchsbaum DJ; Eloubeidi M; Vickers SM; Chhieng DC; Carpenter MD; Sellers JC; Russo S; Diasio RB; Johnson MR
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8773-81. PubMed ID: 16361565
[TBL] [Abstract][Full Text] [Related]
8. Cardiotoxicity of 5-fluorouracil and capecitabine in a pancreatic cancer patient with a novel mutation in the dihydropyrimidine dehydrogenase gene.
Shahrokni A; Rajebi MR; Harold L; Saif MW
JOP; 2009 Mar; 10(2):215-20. PubMed ID: 19287123
[TBL] [Abstract][Full Text] [Related]
9. A Phase I study of weekly intravenous oxaliplatin in combination with oral daily capecitabine and radiation therapy in the neoadjuvant treatment of rectal adenocarcinoma.
Fakih MG; Rajput A; Yang GY; Pendyala L; Toth K; Smith JL; Lawrence DD; Rustum YM
Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1462-70. PubMed ID: 16750332
[TBL] [Abstract][Full Text] [Related]
10. Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study.
Garcia AA; Blessing JA; Darcy KM; Lenz HJ; Zhang W; Hannigan E; Moore DH
Gynecol Oncol; 2007 Mar; 104(3):572-9. PubMed ID: 17049588
[TBL] [Abstract][Full Text] [Related]
11. Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer.
Jakob C; Aust DE; Meyer W; Baretton GB; Schwabe W; Häusler P; Becker H; Liersch T
J Pathol; 2004 Dec; 204(5):562-8. PubMed ID: 15538739
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.
Deenen MJ; Dewit L; Boot H; Beijnen JH; Schellens JH; Cats A
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):e201-7. PubMed ID: 23517808
[TBL] [Abstract][Full Text] [Related]
13. Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study.
Garcia AA; Blessing JA; Lenz HJ; Darcy KM; Mannel RS; Miller DS; Husseinzadeh N;
Gynecol Oncol; 2005 Mar; 96(3):810-7. PubMed ID: 15721430
[TBL] [Abstract][Full Text] [Related]
14. Preoperative radiotherapy and concomitant capecitabine treatment induce thymidylate synthase and thymidine phosphorylase mRNAs in rectal carcinoma.
Kocakova I; Svoboda M; Kubosova K; Chrenko V; Roubalova E; Krejci E; Sefr R; Slampa P; Frgala T; Zaloudik J
Neoplasma; 2007; 54(5):447-53. PubMed ID: 17688376
[TBL] [Abstract][Full Text] [Related]
15. The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer.
Saito K; Khan K; Yu SZ; Ronson S; Rhee J; Li G; Van Echo D; Suntharalingam M; O'Malley BW; Li D
Laryngoscope; 2009 Jan; 119(1):82-8. PubMed ID: 19117293
[TBL] [Abstract][Full Text] [Related]
16. [Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiency].
Coursier S; Martelet S; Guillermet A; Emptoz J; Villier C; Bontemps H
Gastroenterol Clin Biol; 2010 Mar; 34(3):218-23. PubMed ID: 20219304
[TBL] [Abstract][Full Text] [Related]
17. Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation.
Blanquicett C; Gillespie GY; Nabors LB; Miller CR; Bharara S; Buchsbaum DJ; Diasio RB; Johnson MR
Mol Cancer Ther; 2002 Oct; 1(12):1139-45. PubMed ID: 12481438
[TBL] [Abstract][Full Text] [Related]
18. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.
Salonga D; Danenberg KD; Johnson M; Metzger R; Groshen S; Tsao-Wei DD; Lenz HJ; Leichman CG; Leichman L; Diasio RB; Danenberg PV
Clin Cancer Res; 2000 Apr; 6(4):1322-7. PubMed ID: 10778957
[TBL] [Abstract][Full Text] [Related]
19. Prediction of the effect of capecitabine in gastric cancer by immunohistochemical staining of thymidine phosphorylase and dihydropyrimidine dehydrogenase.
Koizumi W; Okayasu I; Hyodo I; Sakamoto J; Kojima H;
Anticancer Drugs; 2008 Sep; 19(8):819-24. PubMed ID: 18690094
[TBL] [Abstract][Full Text] [Related]
20. Evaluations of biomarkers associated with sensitivity to 5-fluorouracil and taxanes for recurrent/advanced breast cancer patients treated with capecitabine-based first-line chemotherapy.
Zhao HY; Huang H; Hu ZH; Huang Y; Lin SX; Tian Y; Lin TY
Anticancer Drugs; 2012 Jun; 23(5):534-42. PubMed ID: 22481060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
